arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2006-12-2-121-124arthyper-1054Research ArticleОБЗОРREVIEWМетаболический синдром и значение иАПФ в его терапии: возможности трандолаприлаMetabolic syndrome and role of ACE inhibitors in its management: focus on trandolaprilМаколкинВ. И.MakolkinV. I.noemail@neicon.ruМосковская медицинская академия им.И.М. СеченоваРоссияMoscow Sechenov Medical academyRussian Federation200628042006122121124Copyright © Маколкин В.И., 20062006Маколкин В.И.Makolkin V.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1054

В обзоре приводятся данные о современных представлениях о метаболическом синдроме, различных критериях его диагностики, подходах к терапии. Показано, что антигипертензивная терапия с помощью ингибиторов АПФ у таких больных является патогенетически оправданной. При этом подчеркивается, что, благодаря своим важным преимуществам - пролонгированному действию, двойному пути выведения и высокой тканевой специфичности трандолаприл может считаться рациональным выбором антигипертензивной терапии для больных, страдающих метаболическим синдромом.

The review describes modern view in metabolic syndrome, diagnostic criteria and management. ACE inhibitors are shown to be indicated to such patients. Trandolapril due to its significant advantages - long duration of action, dual elimination and high tissue activity can be considered predominantly indicated to patients with metabolic syndrome.

метаболический синдромингибитора АПФтрандолаприлmetabolic syndromeACE inhibitorstrandolaprilReferencesKylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämie syndrom. Zentralbl Inn Med 1923;44:105-127.Kylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämie syndrom. Zentralbl Inn Med 1923;44:105-127.Henefeld V, Leonbar dt W. Das metabolische Syndrome. Deutsch Ges Wes 1980;36:545-51.Henefeld V, Leonbar dt W. Das metabolische Syndrome. Deutsch Ges Wes 1980;36:545-51.Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.Бритов A.H., Уметов М.А. Артериальная гипертония при метаболическом синдроме. Возможности антигипертен-зивной терапии. Русский медицинский журнал. 2005, №26, С. 1713-1720.Бритов A.H., Уметов М.А. Артериальная гипертония при метаболическом синдроме. Возможности антигипертен-зивной терапии. Русский медицинский журнал. 2005, №26, С. 1713-1720.Артериальная гипертензия: проблемы и решения. Международный медицинский бюллетень. 2003, №15.Артериальная гипертензия: проблемы и решения. Международный медицинский бюллетень. 2003, №15.Skarfors ET, Litbell НО, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men.J Hypertens 1991; 9:217-23.Skarfors ET, Litbell НО, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men.J Hypertens 1991; 9:217-23.Lissner I, Bengtsson C, Lapidus L et al. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20: 797-801.Lissner I, Bengtsson C, Lapidus L et al. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20: 797-801.Neaton JD, Grimm RH, Prineas RJ et al. Treatment of mild hypertension Study. Final results. JAMA 1993; 270: 713-24.Neaton JD, Grimm RH, Prineas RJ et al. Treatment of mild hypertension Study. Final results. JAMA 1993; 270: 713-24.Hansson L, Lidholm LH, Niskannen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999,353: 611-6.Hansson L, Lidholm LH, Niskannen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999,353: 611-6.Vaur L., Dutrey-Dupegne C., Bonsac J., et al. Diffential effects of missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardvasc Pharmacol 1995; 26: 127-131.Vaur L., Dutrey-Dupegne C., Bonsac J., et al. Diffential effects of missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardvasc Pharmacol 1995; 26: 127-131.Radauceanu A., Virion J.M., Boivin J.M. et al. Time-effectprofile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril. Clin Pharmacology 2002; 16:545-554.Radauceanu A., Virion J.M., Boivin J.M. et al. Time-effectprofile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril. Clin Pharmacology 2002; 16:545-554.Vaur L., Bobrie G., Dutrey-Dupagne C., Dubrocal et.al. Short-Term Effect of Withdrawing Angiotensin Converting Enzyme Inhibitor Therapy on Home Self-Measured Blood Pressure in Hypertensive Patients. Am J Hypertens 1998; 11: 165-173.Vaur L., Bobrie G., Dutrey-Dupagne C., Dubrocal et.al. Short-Term Effect of Withdrawing Angiotensin Converting Enzyme Inhibitor Therapy on Home Self-Measured Blood Pressure in Hypertensive Patients. Am J Hypertens 1998; 11: 165-173.Maarek M., Bensaid J. Efficacy and safety pf trandolapril in overweight hypertensive patients [TRANS]. Annales de Cardiologie et dAngeiologie 1996; 45:343-351.Maarek M., Bensaid J. Efficacy and safety pf trandolapril in overweight hypertensive patients [TRANS]. Annales de Cardiologie et dAngeiologie 1996; 45:343-351.Adalet K., Buyukozturk on behalf of TMTS group. Trandolapril in overweight patients with mild-to-moderate essential hypertension; the Turish multicenter trandolapril study. Current Therapeutic Research 1996; 57: 980-988.Adalet K., Buyukozturk on behalf of TMTS group. Trandolapril in overweight patients with mild-to-moderate essential hypertension; the Turish multicenter trandolapril study. Current Therapeutic Research 1996; 57: 980-988.De la Figuerra M., Rodrigues J.A.S. Duration of trandolapril antihypertensive effect after 24 and 48 hour from last dose. THOR study. Clin Drug Invest 1999; 17:43-50.De la Figuerra M., Rodrigues J.A.S. Duration of trandolapril antihypertensive effect after 24 and 48 hour from last dose. THOR study. Clin Drug Invest 1999; 17:43-50.Pauly N.C., Defcrhouse C. Study of efficacy and tolerance of trandolapril as a single therapy or combined with other antihypertensive agents for long-term treatment of patients with mild or moderate essential hypertension. RU internal report.1990.Pauly N.C., Defcrhouse C. Study of efficacy and tolerance of trandolapril as a single therapy or combined with other antihypertensive agents for long-term treatment of patients with mild or moderate essential hypertension. RU internal report.1990.Kober L., Torp-Pedersen С. on behalf of the TRACE Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New Eng J Med 1995,333: 1670-1676.Kober L., Torp-Pedersen С. on behalf of the TRACE Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New Eng J Med 1995,333: 1670-1676.Маколкин В.И., Подзолков В.И., Ренскова Т.В. Клиническая эффективность трандолаприла у больных гипертонической болезнью. Кардиология 2000; 6:51-54.Маколкин В.И., Подзолков В.И., Ренскова Т.В. Клиническая эффективность трандолаприла у больных гипертонической болезнью. Кардиология 2000; 6:51-54.The PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Eng J Med 2004; 351: 2058-2068The PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Eng J Med 2004; 351: 2058-2068Чазова И.E., Мычка В.Б. Метаболический синдром. М., Media medica. 2004. с. 163.Чазова И.E., Мычка В.Б. Метаболический синдром. М., Media medica. 2004. с. 163.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. М., Реафарм. 2004. С. 141.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. М., Реафарм. 2004. С. 141.

The authors declare that there are no conflicts of interest present.